Quarterly report pursuant to sections 13 or 15(d)

Condensed Statements of Cash Flows (Unaudited)

v2.3.0.11
Condensed Statements of Cash Flows (Unaudited) (USD $)
6 Months Ended 22 Months Ended
Jun. 30, 2011
Jun. 30, 2010
Jun. 30, 2011
Cash flows from operating activities:      
Net loss $ (192,716) $ (98,357) $ (578,832)
Adjustments to reconcile net loss to net cash used in operating activities:      
Amortization of intangible assets 32,143 0 42,857
Stock based compensation 13,118 0 13,240
Changes in:      
Inventory (10,280) 0 (10,059)
Prepaid expenses 18 0 1,207
Accounts payable 157,046 (5,973) 202,963
Accrued expenses (154,112) 39,395 21,581
Net cash used in operating activities (154,783) (64,935) (307,043)
Cash flows from investing activities:      
Net cash acquired in acquisition of Boston Therapeutics, Inc. 0 0 8,397
Net cash provided by investing activities 0 0 8,397
Cash flows from financing activities      
Proceeds from advances - related party 80,000 60,603 197,820
Proceeds from investment in capital stock - related party 0 21,236 21,236
Proceeds from investment in capital stock 500,000 0 520,000
Net cash provided by financing activities 580,000 81,839 739,056
Net increase (decrease) in cash and cash equivalents 425,217 16,904 440,410
Cash and cash equivalents, beginning of period 15,193 23,530 0
Cash and cash equivalents, end of period 440,410 40,434 440,410
Supplemental disclosure of cash flow information:      
Cash paid during the period for:Interest   0 0
Cash paid during the period for:Income taxes   0 0
Acquisition of Boston Therapeutics, Inc.:      
Fair value of assets acquired     985,466
Assumed liabilities     (106,819)
Fair value of common stock issued     878,647
Subscription receivable $ 8,867   $ 8,867